Related Experiment Video
Updated: Jun 22, 2026

Establishment of a Modified Ferric Chloride-Induced Superior Sagittal Sinus Thrombosis
Published on: December 30, 2025
Cerebral venous sinus thrombosis: a case series including thrombolysis
A A Mallick1, P M Sharples, S E Calvert
1Department of Paediatric Neurology, Bristol Royal Hospital for Children, Bristol, UK.
Insights
Cerebral venous sinus thrombosis (CVST) in children presents variably and carries significant risks. While heparin is standard, local thrombolysis showed promise in severe cases, though more evidence is needed for routine use.
Area of Science:
- Pediatric Neurology
- Vascular Neurology
- Pediatric Critical Care
Background:
- Cerebral venous sinus thrombosis (CVST) in children presents with diverse symptoms, posing diagnostic challenges.
- CVST is linked to high rates of severe morbidity and mortality in pediatric populations.
- Optimal treatment strategies for pediatric CVST remain uncertain.
Purpose of the Study:
- To characterize the clinical features of pediatric CVST cases treated at a specialized center.
- To evaluate the efficacy and safety of local thrombolysis as an adjunct treatment for severe pediatric CVST.
Main Methods:
- Systematic electronic database searches using diagnostic labels and ICD codes.
- Retrospective review of medical records for pediatric patients (1 month to <17 years) diagnosed with CVST.
- Analysis of presenting symptoms, clinical signs, underlying conditions, treatments, and outcomes.
Main Results:
- Twenty-one pediatric CVST cases were identified over 8.25 years, with a median age of 7.1 years.
- Common symptoms included headache, vomiting, and visual disturbances; papilledema was a frequent sign.
- Middle ear infection was the most common associated condition; 48% of patients experienced adverse outcomes despite heparin treatment.
Conclusions:
- Pediatric CVST exhibits non-specific symptoms and carries a substantial risk of neurological sequelae.
- Heparin is the primary treatment, but local thrombolysis may offer benefits in select severe cases.
- Further research is required to establish the routine role of thrombolysis in pediatric CVST management.
Background:
Cerebral venous sinus thrombosis (CVST) in children is associated with a high incidence of serious morbidity and mortality. The presenting features are variable. It can be diagnostically challenging and the optimal treatment is uncertain.
Aim:
To describe the features of a series of children with CVST treated in a single paediatric neurology centre and to discuss the role of local thrombolysis.
Methods:
Electronic databases were searched using diagnostic labels and International Classification of Diseases (ICD) codes to identify children aged 1 month to under 17 years with CVST. Their records were reviewed.
Results:
21 children were identified over a period of 8.25 years with a median age of 7.1 years. The presenting symptoms included headache (15 children), vomiting (14 children) and visual disturbance (eight children). Signs found included papilloedema (16 children), fever (six children) and sixth nerve palsy (six children). The most common underlying condition was middle ear infection (13 children). All cases received unfractionated heparin and four severe cases received local pharmacological thrombolysis. 48% of cases had an adverse outcome (death, chronic intracranial hypertension, residual hemiparesis or sixth nerve palsy).
Discussion:
CVST has non-specific presenting features and a high risk of significant morbidity. CVST is typically found in association with a predisposing condition. Although heparin is the mainstay of treatment, thrombolysis may reverse deterioration as seen in three cases in this series. However, there is insufficient evidence to recommend the routine use of thrombolysis at present.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
Venous Thrombosis I: Introduction
Venous Thrombosis IV: Nursing Management
Hemorrhagic Stroke l: Introduction
Hemorrhagic Stroke ll: Pathophysiology